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Background: Ghrelin and peptide YY (PYY) are appetite regulating hormones secreted from the gastrointestinal
tract (gut). Aside from their known effect on energy homeostasis, accumulating data indicates that these gut
hormones also affect bone metabolism. However, data regarding the influence of ghrelin and PYY on bone density
in humans is very limited, and the results are inconclusive. Therefore, this study was designed to investigate the
potential association between circulating ghrelin and PYY with bone density indices in the general population.
Methods: A total of 2257 adult subjects from the CODING (Complex Diseases in the Newfoundland Population:
Environment and Genetics) study participated in this investigation. Acylated ghrelin and total PYY were measured in
serum after a 12-hour fasting, with the Enzyme- Linked Immunosorbent Assay (ELISA) method. Bone mineral density
was measured by dual-energy X-ray absorptiometry at the spine, femoral neck, and total hip. Multiple regression
analyses adjusting for age, BMI, physical activity, smoking, and alcohol consumption were employed to analyze the
association between serum ghrelin and PYY with bone mineral density parameters.
Results: Significant positive associations of ghrelin concentration with L2-L4 BMD, L2-L4 Z-score, femoral neck BMD,
femoral neck Z-score, total hip BMD, and total hip Z-score were found in women. No significant correlations
between ghrelin and bone density indices were present in men. After dividing the female group into pre-
menopausal and post-menopausal, ghrelin was positively correlated with femoral neck Z-score, and total hip
Z-score in pre-menopausal women and L2-L4 BMD, and Z-score in post-menopausal group. Moreover, no
significant association was discovered between serum PYY and bone density at any site.
Conclusion: Our results suggest a beneficial association of circulating ghrelin concentration with bone density in
women at the population level. This association is independent of major confounding factors including BMI,
physical activity, age, alcohol consumption, and smoking. Effect of menopause on this association seemed to be
site specific. However, PYY does not seem to be associated with bone density parameters.
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Osteoporosis is a global problem. According to the Inter-
national Osteoporosis Foundation (IOF) data, the annual
treatment cost for osteoporosis fractures of people in the
workplace in the USA, Canada and Europe is almost 48
billion USD [1]. Therefore, understanding the potential
factors that cause osteoporosis is of great value. Most
cases of osteoporosis are idiopathic because of estrogen
deprivation and aging [2]. However, many other factors
are involved in the pathogenesis of osteoporosis. In popu-
lations aged 50 years and over, secondary causes of osteo-
porosis such as endocrine, gastrointestinal, and connective
tissue diseases, have been found in 41.4% of women and
51.3% of men [3]. In addition, the gastrointestinal hor-
mones, ghrelin and PYY, which aid in energy homeostasis
and weight management, have been found to be involved
in the regulation of bone density [4,5]. Ghrelin is a 28
amino acid appetite stimulant peptide secreted primarily
from the stomach, and PYY is an appetite suppressant
hormone secreted from the enteroendocrine cells of the
ileum and colon [6-8].
The initial investigations regarding the effect of ghrelin
on bone density, that were performed on rodents and
in vitro studies, have shown that ghrelin increases osteo-
blast replication, osteoblast specific gene expression, dif-
ferentiation of osteoblast markers, and bone mineral
density (BMD) [4,9,10]. Human studies regarding the ef-
fect of ghrelin on bone density are very limited and the
results are inconsistent. In a study with 137 elderly men,
ghrelin was positively correlated with femoral neck
BMD [11]. In another study, eleven months after gas-
terectomized surgery, a significant decrease in circulat-
ing ghrelin and bone mineral density was found [12].
However, no association was found between serum
ghrelin concentration with femoral neck BMD or lumbar
spine BMD in 81 Korean men [13]. A study by Makovey
et al. also did not find any significant correlation be-
tween ghrelin concentration and bone mass parameters
in 79 pairs of opposite sex twins [14]. Similarly, Weiss
et al. did not find any association between ghrelin and
BMD in older men or women after adjusting for age and
BMI [15].
Results from animal studies on the effect of PYY on
bone density are also inconsistent. The hypothalamic Y2
receptor serves as the receptor of PYY. Y2 receptor de-
ficient mice have increased trabecular bone volume,
and rate of bone mineralization and formation [5].
However, PYY deficient mice developed a decrease in
trabecular bone mass and osteopenia [16]. Human
studies on the effect of PYY on bone density are ex-
tremely limited in terms of a general population level,
as previous studies have only been performed on special
groups such as anorexic patients or women experien-
cing exercise [17-20].Emerging data suggest the functionally related gut
hormones, ghrelin and PYY, are linked to bone metabol-
ism and BMD. However, data from humans are limited,
the results are contradictory and subject to statistical er-
rors due to small sample size. Also, BMD is a complex
physiological measure and many factors can exert a sig-
nificant effect on it. Therefore, it is important to evalu-
ate whether the possible associations between these two
important gut hormones and bone mineral density are
independent of major confounding factors. The objec-
tives of the current study were: 1) to determine if ghrelin
and PYY are associated with bone density parameters in
a large population-based cohort; 2) to evaluate whether
this possible association is different in men and women,
and also in pre- and post-menopausal women; and 3) to
explore whether the possible associations between
ghrelin or PYY and bone mineral density are independ-




A total of 2,257 subjects from the CODING (Complex
Diseases in the Newfoundland population: Environment
and Genetics) study, including 551 men and 1706 women
were recruited in the present study through advertisement
in public media and word of mouth by previous volun-
teers. All volunteers were at least third-generation New-
foundlander, between the ages of 20 and 79 years old,
without any serious metabolic, cardiovascular, or endo-
crine diseases, and women were not pregnant at the time
of the study.
Ethical considerations
This study was approved by the Health Research Ethics
Authority of the Faculty of Medicine of Memorial Univer-
sity, St. John’s, Newfoundland, Canada. Informed assent
and consent were obtained from all of the volunteers.
Anthropometric measurements
Anthropometric measurements were performed with
participants dressed in a standardized hospital gown.
Standing height was measured to the nearest 0.1 cm
using a fixed stadiometer. Subjects were weighed to the
nearest 0.1 kg using a platform manual scale balance
(Health O Meter, Bridgeview, IL). BMI was calculated
from weight and height in kilograms per square meter
[(weight-kg)/(height-m)2].
Body composition and bone mineral density
measurements
The measurements of bone mineral mass were carried
out by dual-energy X-ray absorptiometry (DXA) Lunar
Prodigy (GE Medical Systems, Madison, WI) equipped
Table 1 Demographic and physical characteristics of
volunteers
Entire cohort Female Male
(n = 2257) (n = 1706) (n = 551)
Mean (SD) Mean (SD) Mean (SD)
Age (yr) 43.1 (12.3) 44 (11.7) 40.3 (13.7)
Weight (kg) 73.4 (15.8) 69.5 (14.1) 85.4 (14.7)
Height (cm) 165.6 (8.5) 162.3 (5.9) 176.1 (6.5)
BMI (kg/m2) 26.7 (5.1) 26.4 (5.2) 27.5 (4.5)
Percent body fat (%) 34.5 (9.4) 37.5 (7.6) 25.1 (7.8)
Percent trunk fat (%) 36.6 (9.7) 38.8 (8.8) 30 (9.3)
Percent android fat (%) 41.9 (11.3) 43.7 (10.6) 36.1 (11.4)
Percent gynoid fat (%) 40.8 (9.8) 44.7 (6.6) 28.6 (8)
Total fat mass (kg) 25.5 (10.3) 26.6 (10.2) 22.1 (9.8)
Total lean mass (kg) 44.6 (10.6) 39.7 (53.9) 59.9 (7.9)
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the same technician in standardized clothing (hospital
gown) with no removable metal objects, while lying flat
on their backs with arms at their sides. In all subjects,
BMD was measured at the sites of lumbar spine, femoral
neck, and total hip. Moreover, Z-score and T-score were
measured for these areas.
According to the World Health Organization (WHO),
T-score ≥ -1 is considered normal, T-score < -1 and > -2.5
is considered osteopenia, and T-score ≤ -2.5 is consid-
ered osteoporosis [21].
Physical activity
The Baecke questionnaire was used for evaluation of the
subject’s physical activity based on the work, sports, and
leisure activity [22].
Blood analysis
Venous blood samples were obtained from all volunteers
in the morning after an overnight fast (12 hours). Serum
samples were isolated from blood and stored at −80°C
until assayed.
Serum acylated ghrelin was measured with an Enzyme -
Linked Immunosorbent Assay (ELISA) method (Human
Acylated Ghrelin Enzyme Immunoassay Kit of Spibio-
bertin pharma). Acylated ghrelin is unstable and sensitive
to de-acylation. Therefore, all samples used for the meas-
urement of acylated ghrelin were thawed for the first time
on the day of analysis, and while running ELSIA kits, all
work was completed on ice. Intra- and inter-assay coeffi-
cients of variation (CV) were 5.7% and 17% respectively.
Serum total PYY concentration was measured with the
ELISA kit from Millipore (Millipore Corporation Phara-
maceuticals, Billerica, MA, USA). The intra-assay CV
was 4.8% - 5.4% and inter-assay CV was 5.1% [23].
Statistical analysis
Statistical analyses were performed using SPSS, version
20.0 (SPSS Inc, Chicago). All tests were two-sided and p
value < 0.05 was considered to be statistically significant.
Evaluation of data normality was performed with the
Kolmograv- Smirnov test. Demographic and physical
characteristics values were expressed as mean (standard
deviation). Logarithmic transformation was performed
for ghrelin, PYY and bone density parameters, except Z-
score (because of the negative values) that were not nor-
mally distributed. These values were reported as median,
minimum and maximum in the results. Analyses were
performed on the entire cohort and, as well, on men and
women separately. Women were further subdivided
according to their menopausal status and the analyses
were conducted between pre- and post-menopausal
groups. Pearson correlation was used to determine the
relationship between ghrelin and PYY and bone mineraldensity indices. Stepwise multiple regression analyses
were used to identify predictors of bone density indices.
Gut hormones and other identified confounders of bone
density such as age, BMI, physical activity, smoking, and
alcohol consumption, were considered independent vari-
ables. Percentage of body fat as the more accurate meas-
ure for body composition was also replaced with BMI to
see whether the effect of body fat percentage differed
from BMI. The results were similar. Therefore, in order
to remain consistent with previous literature, BMI was
entered into the model.Results
Subject characteristics
Mean and standard deviation of demographic and
physical characteristics of the subjects are presented in
Table 1. Ghrelin, PYY, and bone density parameters are
described as median, minimum and maximum in
Table 2. According to the WHO criteria (based on the
L2-L4 T-score), 80.8% of volunteers had normal bone
density, 16.9% were osteopenic, and 2.2% were osteo-
porotic. According to the femoral neck T-score, 76.6%
were normal, 22.6% and 0.7% met the criteria of
osteopenia and osteoporosis respectively, and based on
total hip T-score 83.5%, 16.2%, and 0.3% were normal,
osteopenic, and osteoporotic respectively.Pearson correlation of ghrelin and PYY with bone density
measures
Pearson correlation analyses showed positive correla-
tions between ghrelin and L2-L4 Z-score, femoral neck
Z-score, and total hip Z-score in the entire cohort (r =
0.05, p = 0.03, r = 0.07, p = 0.004, and r = 0.05, p = 0.03
Table 2 Descriptive statistics for ghrelin, PYY, and bone density indices
Variables Entire cohort Female Male
Median Min-Max Median Min-Max Median Min-Max
Ghrelin (pg/ml) 194.7 0.74–2329.09 193.44 0.74–2329.09 196.73 2.12–2289.26
PYY (pg/ml) 95 3.67–368.53 92.52 3.67–368.53 103.67 8.37–364.66
Spine BMD (g/cm2) 1.21 0.76–1.85 1.20 0.76–1.85 1.26 0.81–1.78
Left Hip BMD (g/cm2) 0.98 0.52–1.83 0.96 0.52–1.65 1.04 0.67–1.83
Total hip BMD (g/cm2) 1.02 0.61–1.68 0.99 0.61–1.58 1.1 0.76–1.68
L2-L4 Z score (%) 0.2 −4.1–6.1 0.2 −4.1–6.1 0.1 −3.4–4.8
Femur Neck Z score (%) 0.1 −2.5–5.7 0.2 −2.5–5 0.1 −2–5.7
Total hip Z-score (%) 0.2 −3.12–4.4 0.21 −3.12–4.12 0.18 −2.63–4.4
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p = 0.003, and r = 0.07, p = 0.006 respectively).
For PYY, there was no significant association with any
of the bone density parameters either in the entire co-
hort or in the males and females separately.Table 3 Regression analyses of ghrelin with BMD and Z-score
Female
Variables β∗ (95% CI)✝ P
L2-L4 BMD Age −0.003 (−0.003, −0.002) <0.00
BMI 0.005 (0.004, 0.007) <0.00
Smoking −0.043 (−0.065, −0.021) <0.00
Ghrelin 0.009 (0.002, 0.017) 0.015
Femoral Neck BMD Age −0.004 (−0.005, −0.004) <0.00
BMI 0.008 (0.006, 0.009) <0.00
PA2 0.011 (0.007, 0.016) <0.00
Smoking −0.044 (−0.065, −0.023) <0.00
Ghrelin 0.008 (0.000, 0.015) 0.04
Total Hip BMD BMI 0.011 (0.009, 0.012) <0.00
Age −0.003 (−0.003, −0.002) <0.00
PA 0.009 (0.005, 0.014) <0.00
Smoking −0.036 (−0.057, −0.016) <0.00
Ghrelin 0.009 (0.002, 0.016) 0.009
L2-L4 Z-score Smoking −0.458 (−0.675, −0.241) <0.00
Ghrelin 0.102 (0.027, 0.177) 0.007
Femoral Neck Z-score Smoking −0.338 (−0.502, −0.173) <0.00
PA 0.078 (0.044, 0.113) <0.00
Ghrelin 0.073 (0.015, 0.131) 0.013
BMI 0.013 (0.003, 0.024) 0.015
Total Hip Z-score BMI 0.043 (0.033, 0.053) <0.00
Smoking −0.286 (−0.447, −0.125) 0.001
PA 0.059 (0.026, 0.093) 0.001
Ghrelin 0.081 (0.024, 0.137) 0.005
1Regression model adjusted for age, BMI, alcohol consumption, physical activity, an
Confidence Interval.Multiple regression analyses of ghrelin and PYY with
bone density indices adjusting for BMI, age, physical
activity, smoking and alcohol consumption
Stepwise multiple regression analyses were performed to
clarify the determinants of BMD and Z-score in maless in women and men1
Male
R2 Variables β (95% CI) P R2
1 0.1 BMI 0.006 (0.003, 0.009) <0.001 0.045
1 Age −0.001 (−0.002, 0.000) 0.012
1
1 0.238 Age −.006 (−0.006, −0.005) <0.001 0.361
1 BMI .012 (0.010, 0.015) <0.001
1 PA .015 (0.007, 0.023) <0.001
1 Smoking −.047 (−0.083, −0.010) 0.012
Alcohol .001 (0.000, 0.002) 0.020
1 0.234 BMI .013 (0.011, 0.016) <0.001 0.247
1 Age −.002 (−0.003, −0.001) <0.001
1 PA .013 (0.005, 0.020) 0.002
1 Alcohol .001 (0.000, 0.002) 0.019
Smoking −.037 (−0.072, −0.002) 0.036
1 0.022
1 0.04 PA 0.158 (0.092, 0.224) <0.001 0.085
1 BMI 0.055 (0.031, 0.079) <0.001
1 0.076 BMI 0.08 (0.058, 0.102) <0.001 0.137
PA 0.122 (0.059, 0.185) <0.001
Alcohol 0.007 (0.000, 0.015) 0.042
d smoking2 Physical Activity* Unstandardized β coefficients ✝95%
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positive associations between ghrelin and L2-L4 BMD
and Z-score, femoral neck BMD and Z-score, and total
hip BMD and Z-score (Table 3). [For Z-score, age was
not included in the model because Z-score is the num-
ber of standard deviations above or below what is nor-
mally expected for someone of their age, sex, and ethnic
or racial origin].
For PYY after entering the variables into the model, no
significant association was found between PYY and
BMD or Z-score values.Influence of menopause on the relationship between
ghrelin and bone density
To evaluate the influence of menopause on the associ-
ation between ghrelin and bone density, multiple regres-
sion analyses were performed in females after they were
divided into pre- and post-menopausal groups. Signifi-
cant associations were seen between ghrelin and femoral
neck and total hip Z-scores in pre-menopausal women.
In post-menopausal group ghrelin was positively associ-
ated with L2-L4 BMD, and Z-score (Table 4).Table 4 Regression analyses of ghrelin with BMD and Z-score
Pre-menopausal (N = 971)
Variables β* (95% CI)✝ P
L2-L4 BMD BMI 0.005 (0.003, 0.006) <0.00
Smoking −0.032 (−0.059, −0.004) 0.023
Femoral Neck BMD BMI 0.008 (0.006, 0.010) <0.00
Age −0.003 (−0.004, −0.002) <0.00
PA2 0.013 (0.007, 0.019) <0.00
Smoking −0.039 (−0.067, −0.010) 0.007
Total Hip BMD BMI 0.01 (0.008, 0.011) <0.00
PA 0.014 (0.008, 0.019) <0.00
Smoking −0.034 (−0.063, −0.006) 0.017
L2-L4 Z-score Smoking −0.394 (−0.673, −0.116) 0.006
Femoral Neck Z-score PA 0.106 (0.058, 0.154) <0.00
Smoking −0.304 (−0.538, −0.071) 0.011
BMI 0.018 (0.003, 0.033) 0.018
Ghrelin 0.096 (0.017, 0.175) 0.018
Total Hip Z-score BMI 0.043 (0.028, 0.058) <0.00
PA 0.092 (0.044, 0.140) <0.00
Smoking −0.315 (−0.546, −0.085) 0.007
Ghrelin 0.107 (0.029, 0.185) 0.008
1Regression model adjusted for age, BMI, alcohol consumption, physical activity, an
Confidence Interval.Discussion
In the present study, we examined the associations be-
tween the levels of circulating ghrelin and PYY, with
bone mineral density indices controlling for major
confounding factors in the Newfoundland population.
The most important finding from our study is that cir-
culating fasting ghrelin concentration is significantly and
positively correlated with femoral neck, total hip, and
lumbar spine bone mineral densities and Z-scores in
females. More importantly, we demonstrated that the as-
sociation of ghrelin with bone mineral density is inde-
pendent of age, body composition, alcohol consumption,
physical activity, and smoking. We found out that serum
PYY is not significantly correlated with any of the bone
density measures in this study. To our knowledge this is
the largest human study that simultaneously evaluated
the relationship of the two gut hormones, ghrelin and
PYY, with bone mineral density with comprehensive
control of major confounding factors.
Similarly, a study with the sample size of 137 men
aged 55 years or older revealed a positive correlation
between ghrelin and femoral neck BMD [11]. The aver-
age ages in both women and men in our study ares in women based on menopausal status1
Post-menopausal (N = 653)
R2 Variables β (95% CI) P R2
1 0.05 BMI 0.006 (0.003, 0.008) <0.001 0.088
Smoking −0.055 (−0.092, −0.017) 0.005
Age −0.002 (−0.004, −0.001) 0.001
Ghrelin 0.014 (0.001, 0.027) 0.037
1 0.139 Age −0.004 (−0.006, −0.003) <0.001 0.195
1 BMI 0.007 (0.005, 0.009) <0.001
1 Smoking −0.044 (−0.077, −0.012) .007
PA 0.008 (0.001, 0.015) .019
1 0.164 BMI 0.011 (0.009, 0.013) <0.001 0.263
1 Age −0.003 (−0.004, −0.002) <0.001
Smoking −0.041 (−0.071, −0.011) 0.008
0.012 Smoking −0.596 (−0.964, −0.229) 0.002 0.034
Ghrelin 0.135 (0.006, 0.263) 0.04
1 0.051 Smoking −0.421 (−0.658, −0.185) .001 0.025
1 0.083 BMI 0.043 (0.029, 0.057) <0.001 0.084
1 Smoking −0.32 (−0.552, −0.089) 0.007
d smoking2 Physical Activity* Unstandardized β coefficients✝ 95%
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Data from both cultured cell based and animal experi-
ments supported the significant association between
ghrelin and BMD. An animal study has shown that
ghrelin receptors are present in osteoblasts and ghrelin
can increase osteoblast proliferation and differentiation
markers [4]. Moreover, gasterectomy in mice, in which
ghrelin secretion is significantly reduced, can cause de-
creased bone density [24].
The mechanism by which ghrelin increases bone
mineral density has yet to be completely understood.
Ghrelin is a natural ligand for the growth hormone se-
cretagogue receptor, and growth hormone increases
bone density. Therefore, ghrelin may also affect bone
density through the growth hormone related pathway.
Moreover, previous studies have shown that osteoblasts
express the ghrelin receptor. Ghrelin stimulates both
osteoblast cell proliferation and differentiation [4]. How-
ever, Delhanty et al. did not find expression of GHS-R1a
(Growth hormone secretagogue Receptor-1a) in osteo-
blasts. They found out that the effect of ghrelin on bone
density is through ERK and PI3K, and MAPK pathway
[25]. A recent study on wild type and ghrelin receptor
deficient mice has shown that ghrelin can inhibit
osteoclastogenesis and this effect is age dependent.
With aging inhibitory effect of ghrelin on osteoclasts
increases [26].
Data from some studies do not support the association
between ghrelin and bone density. In ghrelin knockout
mice, bone mineral density and bone mineral content
between ghrelin −/− mice and wild type mice were simi-
lar [27]. There was no significant association between
ghrelin and BMD in a study consisting of 80 male adults.
In this study, the effect of alcohol, smoking, and physical
activity was not controlled [13]. Also, in a study with
977 old adults, no significant association was found be-
tween ghrelin and BMD in either sex after controlling
for age and BMI [15]. Ghrelin has extremely high stand-
ard deviation, and therefore studies on ghrelin need a
very large sample size to have reasonable statistical
power. Otherwise it is likely to have type II error. Cau-
tion should be taken on either negative or positive re-
sults from the studies with small sample sizes.
In our study, the positive association between ghrelin
and BMD was found only in females. The reason for the
sex difference in the association between ghrelin and
BMD is unknown, and could be due to the relatively
smaller number of male subjects, differences in sex hor-
mones, or other unknown factors.
Bone density is a complex physiological marker. Many
factors can potentially be involved in the regulation of
BMD. In the present study, one of the important goals
was to clarify if the significant positive association ofghrelin with bone mineral density is secondary to any
confounding factor. We were able to demonstrate that
the positive association is indeed independent of the
major confounding factors available in the study.
Physical activity and age are important in determining
bone density [28,29]. In our study, ghrelin was positively
correlated with age. Previous primary studies have
shown that bone density decreases at most sites after
age of fifty due to trabecularization of cortical bones
[30,31]. Physical activity, especially weight-bearing
sport-specific activity, is positively associated with fem-
oral neck bone density after adjustment for age, sex,
ethnicity, smoking, menopausal status, lean body mass,
and total body fat [32]. Even after adjusting for age and
physical activity, the association of ghrelin with bone
density indices remained significant.
Alcohol consumption in adolescence can also cause
reduction in bone density [33]. In our study, almost 77%
of the volunteers reported they consume alcohol (irre-
spective of the dosage of the alcohol they drink). There-
fore alcohol consumption was adjusted in the analyses
as well, and it did not affect the significant results.
Previous studies on the effect of menopause on ghrelin
are contradictory. In a study on 57 females, the level of
ghrelin was lower in peri-menopausal and post-menopausal
women compared to pre-menopausal group, and ghrelin
seemed to be positively correlated with bone density [34].
However, another study did not reveal any difference be-
tween ghrelin levels of pre- and post-menopausal women
[35]. To eliminate the potential influence of menopausal
status, the females were divided into two groups based on
the menopausal status. We found positive associations
between ghrelin and femoral neck, and total hip Z-
scores in pre-menopausal women. In post-menopausal
group, ghrelin was associated positively with L2-L4
BMD and Z-score. Although this difference might be
consequence of changes in sex hormones caused by
menopause, factors such as physical activity, body
composition, and the smaller number of women in
post-menopausal group might also be the reason for the
difference observed between these groups.
In the present study, fasting PYY was not significantly
associated with bone density. Previous studies evaluated
the association between PYY and bone density in meta-
bolic diseases that affect PYY such as anorexia nervosa
or in special groups such as athletes. In two studies on
anorexia nervosa patients, PYY was negatively associated
with bone density [19,36]. However, these studies were
done in patients that had lower body weight and usually
lower BMD because of the anorexia nervosa [37]. Con-
sidering many important factors including smoking, al-
cohol consumption, and physical activity, it would be
difficult to interpret the effect of PYY on bone density in
this special group and in small study.
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in 3 groups of amenorrheic athletes, eumenorrheic athletes,
and non-athletic controls, PYY was a negative predictor of
lumbar Z-score. In their study, although they controlled for
lean mass, other confounding factors such as physical
activity, alcohol consumption, and smoking were not en-
tered in the regression model [20]. The amount of physical
activity and also age may exert significant influence on
BMD and appetite, which in turn could affect PYY.
We did not find any significant association between
PYY and bone density indices. Our data suggest that
PYY is not likely an important player in determining
BMD. The effect of PYY on bone density, which was
reported in previous studies, might be through Y2 recep-
tors to reduce NPY [5]. Also, effect of PYY on bone
density might be secondary to its effects on body com-
position and BMI.
Our study had certain limitations. We performed a
cross-sectional study and correlation data collected do
not prove causality. Therefore, interventional studies of
ghrelin administration in osteoporotic patients might be
necessary to further evaluate this finding. Also, vitamin
D and bone density markers were not measured in our
study. Another limitation of our study was that the
volunteer-based participation of the subjects in our study
resulted in the recruitment of volunteers, where the num-
ber of males was less than females. Despite these limita-
tions we are confident that considering the effect of two
important gut hormones simultaneously with controlling
most of the confounding factors in a big population based
study made our results unique and reliable.Conclusions
The present study investigated the relationship of two
gut hormones, ghrelin and PYY, with BMD in the New-
foundland population. To our knowledge, this is the first
study that simultaneously investigates the association of
ghrelin and PYY with BMD. It is also the largest popula-
tion based study adjusting for the most confounding fac-
tors in the analysis. With such a large sample size, the
present study had significantly higher power than all
reported studies to detect the potential statistical signals.
The significant positive associations of circulating ghrelin
with BMD in women suggest that high levels of ghrelin
might have beneficial effects on bone density in the female
population. The beneficial effect is independent of BMI,
physical activity, age, smoking, and alcohol consumption.
The clinical significance of ghrelin on BMD warranted fu-
ture studies. In our study, PYY was not a significant player
in determining bone density.Competing interests
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